Common Contracts
4 similar Employment Agreement contracts by Entrada Therapeutics, Inc.
EMPLOYMENT AGREEMENTEmployment Agreement • October 25th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) dated as of [DATE] is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and [INSERT] (the “Executive”). This Agreement shall become effective as of [DATE], which, unless otherwise provided by the Company, will be the first day of the Executive’s employment with the Company (the “Start Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 25th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) dated as of October 20, 2021 is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and Dipal Doshi (the “Executive”). This Agreement shall become effective as of the closing of the Company’s first underwritten public offering (the “IPO”) of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated May 14, 2019 and (ii) any offer letter, other employment agreement, severance agreement and severance policy between the Executive and the Company ((i) and (ii) collectively the “Superseded Agreements”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 25th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) dated as of October 20, 2021 is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and Natarajan Sethuraman (the “Executive”). This Agreement shall become effective as of the closing of the Company’s first underwritten public offering (the “IPO”) of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated March 4, 2019 and (ii) any offer letter, other employment agreement, severance agreement and severance policy between the Executive and the Company ((i) and (ii) collectively the “Superseded Agreements”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 25th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) dated as of October 20, 2021 is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and Nathan Dowden (the “Executive”). This Agreement shall become effective as of the closing of the Company’s first underwritten public offering (the “IPO”) of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated November 4, 2019 and (ii) any offer letter, other employment agreement, severance agreement and severance policy between the Executive and the Company ((i) and (ii) collectively the “Superseded Agreements”).
